

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE YEAR ENDED 31 DECEMBER 2023

On 26 January 2024, Dong-E-E-Jiao released its results estimate for the year ended 31 December 2023.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 9.00% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.50% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 22.31% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 26 January 2024, Dong-E-E-Jiao released its results estimate for the year ended 31 December 2023, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the year ended 31 December 2023 is estimated to range from approximately RMB1,100 million to RMB1,160 million (as compared to the same period last year of net profit of approximately RMB779.9981 million), net profit excluding non-recurring gain or loss is estimated to range from approximately RMB1,030 million to RMB1,100 million (as compared to the same period last year of net profit of approximately RMB699.8299 million), basic earnings per share is estimated to range from approximately RMB1.71 per share to approximately RMB1.80 per share (as compared to same period last year of profit per share of approximately RMB1.21 per share) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

In 2023, Dong-E-E-Jiao closely focused on the theme of “growth and efficiency” and continued to deeply practise “reshaping values, businesses, organisation and ethos.” It adheres to a consumer-centric approach, comprehensively rejuvenates and renews the brand from multiple perspectives, strengthens brand barriers through powerful media, and enhances audience penetration through high-quality innovation. It firmly implements the dual growth model driven by both pharmaceuticals and health consumer products, systematically builds a refined management system, strengthens terminal sales, and taps into growth potential. It solidly executes the new product cultivation strategy, with a focus on building the “Royal Weichang 1619” brand for men’s health supplements and continuously enriching the non-E-Jiao gelatin product line. Dong-E-E-Jiao comprehensively launches the innovative platform with “one center” and “three highlands”, gathers top expert resources to support research and development and leads the innovation and upgrading of the industry chain.

In the future, Dong-E-E-Jiao will firmly shoulder the mission and responsibility of playing a leading role in the inheritance and innovation of traditional Chinese medicine culture. It will deeply promote the dual growth model driven for business model, adhere to the value leadership of “Zi Bu Guo Bao Dong-E-E-Jiao,” focus on ensuring the growth of compound E-Jiao paste products across the entire industry chain, actively expand health consumer products represented by “Taohuajie” E-Jiao cake, gradually build the “Royal Weichang 1619” matrix of men’s health supplements, and make every effort to create a top-notch health series brand and to become the most trusted leader in nourishment and health for the general public.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the annual report for the year ended 31 December 2023 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 26 January 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.